LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Atvērts

SektorsVeselības aprūpe

101.44 3.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

98.45

Max

102.91

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.682 49.8
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 367M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+10.72% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	358M 19B
Iepriekšējā atvēršanas cena	98.4
Iepriekšējā slēgšanas cena	101.44

Ziņu noskaņojums

By Acuity

37%

63%

103 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. maijs 23:47 UTC

Tirgus saruna

Gold Falls on Renewed Inflation Concerns -- Market Talk

2026. g. 10. maijs 23:44 UTC

Tirgus saruna

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2026. g. 10. maijs 23:38 UTC

Tirgus saruna

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

2026. g. 10. maijs 23:14 UTC

Tirgus saruna

Australia's Political Map Continues to Be Redrawn -- Market Talk

2026. g. 10. maijs 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium: Expects Deal to Close in 1Q FY27

2026. g. 10. maijs 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

2026. g. 10. maijs 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

2026. g. 10. maijs 10:21 UTC

Peļņas

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

2026. g. 9. maijs 06:05 UTC

Peļņas

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

2026. g. 8. maijs 23:55 UTC

Peļņas

Review & Preview: Still Going Strong -- Barrons.com

2026. g. 8. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 20:49 UTC

Peļņas

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026. g. 8. maijs 20:25 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026. g. 8. maijs 19:43 UTC

Peļņas

Cencosud 1Q Net $115M

2026. g. 8. maijs 19:20 UTC

Tirgus saruna

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026. g. 8. maijs 19:18 UTC

Peļņas

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026. g. 8. maijs 19:16 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:08 UTC

Peļņas

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026. g. 8. maijs 19:05 UTC

Peļņas

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026. g. 8. maijs 19:02 UTC

Tirgus saruna

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026. g. 8. maijs 18:51 UTC

Peļņas

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026. g. 8. maijs 18:49 UTC

Peļņas

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026. g. 8. maijs 18:41 UTC

Peļņas

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026. g. 8. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026. g. 8. maijs 17:14 UTC

Peļņas

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026. g. 8. maijs 17:04 UTC

Tirgus saruna

Zcash Caps Off Parabolic Week -- Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 8. maijs 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 8. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

10.72% augšup

Prognoze 12 mēnešiem

Vidējais 109.13 USD 10.72%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

103 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation